What does the evidence say about Barley Beta Glucan Blood Glucose Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Barley Beta Glucan Blood Glucose Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - 2021a As outlined in the General scientific guidance for stakeholders on health claim applications (EFSA NDA Panel, ), it is the responsibility of the applicant to provide the totality of the available evidence. [Turck Dominique (2026); evidence level 4] - According to the EFSA guidance (EFSA NDA Panel, ), the scientific evidence for the substantiation of health claims on the reduction of postprandial blood glucose responses can be obtained from human intervention studies showing a decrease in blood glucose concentrations at different time points after consumption of a test food during an appropriate period of time (i.e. [Turck Dominique (2026); evidence level 4] - for individuals with impaired glucose tolerance (IGT)), as long as postprandial insulinaemic responses are not disproportionally increased (EFSA NDA Panel, ). [Turck Dominique (2026); evidence level 4] - EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 16(3) of Regulation (EC) No 1924/2006. [Turck Dominique (2026); evidence level 4] - 2021b As outlined in the General scientific guidance for stakeholders on health claim applications (EFSA NDA Panel, ), it is the responsibility of the applicant to provide the totality of the available evidence. [Turck Dominique (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.